JP2024016042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016042A5 JP2024016042A5 JP2023177190A JP2023177190A JP2024016042A5 JP 2024016042 A5 JP2024016042 A5 JP 2024016042A5 JP 2023177190 A JP2023177190 A JP 2023177190A JP 2023177190 A JP2023177190 A JP 2023177190A JP 2024016042 A5 JP2024016042 A5 JP 2024016042A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cdr
- seq
- administered
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025089576A JP7904366B2 (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598402P | 2017-12-13 | 2017-12-13 | |
| US62/598,402 | 2017-12-13 | ||
| US201862701354P | 2018-07-20 | 2018-07-20 | |
| US62/701,354 | 2018-07-20 | ||
| PCT/US2018/065568 WO2019118791A1 (en) | 2017-12-13 | 2018-12-13 | Fcrn antibodies and methods of use thereof |
| JP2020532551A JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532551A Division JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025089576A Division JP7904366B2 (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024016042A JP2024016042A (ja) | 2024-02-06 |
| JP2024016042A5 true JP2024016042A5 (cg-RX-API-DMAC10.html) | 2024-07-04 |
| JP7690538B2 JP7690538B2 (ja) | 2025-06-10 |
Family
ID=65041911
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532551A Active JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2023177190A Active JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2025089576A Active JP7904366B2 (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532551A Active JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025089576A Active JP7904366B2 (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Country Status (11)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6853178B2 (ja) | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| CA3183153A1 (en) * | 2020-06-17 | 2021-12-23 | Christian HINDERER | Compositions and methods for treatment of gene therapy patients |
| CN116782939A (zh) * | 2020-11-06 | 2023-09-19 | 动量制药公司 | FcRn抗体及其使用方法 |
| CA3200972A1 (en) * | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| MX2023012032A (es) * | 2021-04-12 | 2023-12-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos para tratar la miastenia gravis pediátrica. |
| CN116234827B (zh) * | 2021-09-03 | 2026-07-14 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN114129730A (zh) * | 2021-09-16 | 2022-03-04 | 宁夏大学 | FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用 |
| MX2024007806A (es) * | 2022-01-17 | 2024-07-04 | argenx BV | Metodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos. |
| KR20250037789A (ko) | 2022-06-15 | 2025-03-18 | 아르젠엑스 비브이 | Fcrn/항원-결합 분자 및 사용 방법 |
| US20250034260A1 (en) | 2023-07-05 | 2025-01-30 | Sanofi | Fcrn antagonists for treatment of igg-related diseases and disorders |
| JP2026526949A (ja) | 2023-07-31 | 2026-08-10 | メディトックス インク． | 抗体及びそれを含む免疫疾患治療用薬学的組成物 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CA2534973A1 (en) | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| WO2007104529A2 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| US8273351B2 (en) | 2008-04-25 | 2012-09-25 | Dyax Corp. | Fc receptor binding proteins |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| US9067997B2 (en) * | 2011-05-25 | 2015-06-30 | Innate Pharma Sa | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders |
| BR112013030352B1 (pt) | 2011-06-02 | 2020-05-19 | Dyax Corp. | anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| EP2991666B1 (en) | 2013-05-02 | 2020-03-25 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| EP4241852A3 (en) | 2014-04-30 | 2023-11-15 | Hanall Biopharma Co., Ltd. | Antibody binding to fcrn for treating autoimmune diseases |
| JP6853178B2 (ja) | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| CA3022547A1 (en) * | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| JP6913527B2 (ja) | 2017-06-22 | 2021-08-04 | 株式会社小松製作所 | 油圧ポンプおよびモータ |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| EP3762027A4 (en) | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| IL280280B2 (en) | 2018-07-20 | 2024-11-01 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| JP7518821B2 (ja) | 2018-10-16 | 2024-07-18 | ユーシービー バイオファルマ エスアールエル | 重症筋無力症の治療方法 |
| CA3148826A1 (en) | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| CA3200972A1 (en) | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
-
2018
- 2018-12-13 BR BR112020011310-7A patent/BR112020011310A2/pt unknown
- 2018-12-13 KR KR1020257042733A patent/KR20260008175A/ko active Pending
- 2018-12-13 JP JP2020532551A patent/JP7420720B2/ja active Active
- 2018-12-13 EP EP18836751.0A patent/EP3723802A1/en active Pending
- 2018-12-13 AU AU2018386193A patent/AU2018386193B2/en active Active
- 2018-12-13 SG SG11202005021PA patent/SG11202005021PA/en unknown
- 2018-12-13 US US16/771,147 patent/US11773168B2/en active Active
- 2018-12-13 CN CN201880089334.7A patent/CN111712259A/zh active Pending
- 2018-12-13 WO PCT/US2018/065568 patent/WO2019118791A1/en not_active Ceased
- 2018-12-13 KR KR1020207019955A patent/KR102904658B1/ko active Active
- 2018-12-13 CA CA3085751A patent/CA3085751A1/en active Pending
-
2020
- 2020-06-02 IL IL275070A patent/IL275070A/en unknown
-
2023
- 2023-08-18 US US18/452,346 patent/US20240158509A1/en not_active Abandoned
- 2023-10-13 JP JP2023177190A patent/JP7690538B2/ja active Active
-
2025
- 2025-05-29 JP JP2025089576A patent/JP7904366B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506786A5 (cg-RX-API-DMAC10.html) | ||
| JP2019526540A5 (cg-RX-API-DMAC10.html) | ||
| JP7442575B2 (ja) | Ｆｃｒｎ抗体及びその使用方法 | |
| US20220144946A1 (en) | Fcrn antibodies and methods of use thereof | |
| AU2008207338B2 (en) | Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex | |
| CN114630678A (zh) | FcRn抗体及其使用方法 | |
| BRPI0711908B1 (pt) | Anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo | |
| JP2021525718A5 (cg-RX-API-DMAC10.html) | ||
| EA050428B1 (ru) | АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| EA051865B1 (ru) | Антитела к fcrn и способы их применения | |
| HK40072884A (en) | Fcrn antibodies and methods of use thereof | |
| JPH04120025A (ja) | インターロイキン―６の作用増強剤 | |
| JPH07126299A (ja) | ヒト型モノクローナル抗体 |